Pazopanib is a multitargeted tyrosine kinase inhibitor that suppresses angiogenesis and proliferation of tumor cells. To increase its bioavailability, a model of a liposomal dosage form of pazopanib is developed and its main pharmaceutical and technological characteristics are determined. It is found that a composition including the active substance, egg phosphatidylcholine, cholesterol, and poly(ethylene glycol) lipid in a mass ratio of 1 : 75 : 7.5 : 0.75 possesses the best properties (size, polydispersity index, and surface charge). To determine the pazopanib concentration in model mixtures, ultraviolet (UV) spectrophotometry is used, which demonstrates the specificity of the method and its linearity (the ability to obtain results within a specified range that are directly proportional to the concentration of the analyte in the sample). The liposomal dispersion is stabilized by lyophilization, and a 10%-aqueous sucrose solution is selected as a cryoprotectant. Pazopanib in the final product is determined by high-performance liquid chromatography. The stability of the lyophilized liposomal dosage form for six months at a storage temperature of no higher than –18°C is shown.